Drugmaker with rare disease work · based in Hampton, United States · founded 1983 · ticker CLDX · celldex.com
Celldex Therapeutics is a biopharmaceutical company developing therapeuticantibodies for patients with severe inflammatory, allergic, autoimmune, and other rare diseases. The company's lead program, barzolvolimab (CDX-0159), is a monoclonal antibody being tested in chronic spontaneous urticaria, chronic inducible urticaria and atopic dermatitis. Celldex stopped development in eosinophilicesophagitis after Phase 2 results in August 2025, and stopped its Phase 2 prurigo nodularis study in July 2026.
Celldex Therapeutics clinical trials
We did not find active Celldex Therapeutics trials for the rare diseases we track on ClinicalTrials.gov right now.
More about Celldex Therapeutics
On September 22, 2026, Celldex reported that both Phase 3 EMBARQ-CSU trials in chronic spontaneous urticaria met their primary endpoint (change in UAS7 at week 12) and all key secondary endpoints, with 42-46% of treated patients reaching complete response (a UAS7 score of 0) at week 12, against 9-13% on placebo. Celldex plans to submit a BLA to the FDA in 2027.
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Celldex Therapeutics's own site is celldex.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Questions about Celldex Therapeutics
Celldex Therapeutics is a biopharmaceutical company developing therapeuticantibodies for patients with severe inflammatory, allergic, autoimmune, and other rare diseases. The company's lead program, barzolvolimab (CDX-0159), is a monoclonal antibody being tested in chronic spontaneous urticaria, chronic inducible urticaria and atopic dermatitis. Celldex stopped development in eosinophilicesophagitis after Phase 2 results in August 2025, and stopped its Phase 2 prurigo nodularis study in July 2026.
On September 22, 2026, Celldex reported that both Phase 3 EMBARQ-CSU trials in chronic spontaneous urticaria met their primary endpoint (change in UAS7 at week 12) and all key secondary endpoints, with 42-46% of treated patients reaching complete response (a UAS7 score of 0) at week 12, against 9-13% on placebo. Celldex plans to submit a BLA to the FDA in 2027.
Celldex Therapeutics is a diversified pharmaceutical company headquartered in Hampton, United States, founded in 1983. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 0 active rare disease programs. Many of its rare disease treatments hold orphan drug designations from the FDA.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Celldex Therapeutics, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Celldex Therapeutics label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Celldex Therapeutics is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Celldex Therapeutics was founded in 1983 and is headquartered in Hampton, United States. The company has been active for 43 years. It trades publicly under the ticker symbol CLDX.